The oncology franchise carried growth for Johnson & Johnson in the third quarter and continues to increase its prominence for J&J’s pharmaceuticals business overall. But some of the cancer growth will be dimmed by potential generic competition to its prostate cancer blockbuster Zytiga.
While Zytiga comprises about 5% of J&J’s pharmaceutical sales, according to a Morningstar estimate, J&J reported its pharma segment growth...








